|
MechanismCD276 inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
100 Clinical Results associated with Beijing Qinghui Liannuo Biotechnology Co Ltd.
0 Patents (Medical) associated with Beijing Qinghui Liannuo Biotechnology Co Ltd.
100 Deals associated with Beijing Qinghui Liannuo Biotechnology Co Ltd.
100 Translational Medicine associated with Beijing Qinghui Liannuo Biotechnology Co Ltd.